|
| Status |
Public on Jul 28, 2006 |
| Title |
Ad+veh replicate2 b |
| Sample type |
RNA |
| |
|
| Source name |
MCF-7 breast cancer cells
|
| Organism |
Homo sapiens |
| Characteristics |
Ad(moi10)-infected, vehicle-treated for 24hr
|
| Extracted molecule |
total RNA |
| Extraction protocol |
MCF-7 cells expressing endogenous ERalpha were plated in 100mm dish in 5% CD-stripped calf serum. Cells were infected with adenovirus carrying either estrogen receptor beta (AdERb) or no insert (Ad) at multiplicity of infection (moi) of 5 or 50. Cells were infected with adenovirus for a period of 48hr before treatment with ligand (vehicle control (veh), 10nM 17beta-estradiol (E2), or 10nM trans-hydroxytamoxifen (TOT)) for a additional period of 24hr before harvest. Total RNA was extracted using 1mL of TRIzol (Invitrogen) per 100mm dish.
|
| Label |
biotin
|
| Label protocol |
Approximately 8 micrograms of total RNA was processed to produce biotinylated cRNA targets.
|
| |
|
| Hybridization protocol |
standard Affymetrix procedures
|
| Scan protocol |
standard Affymetrix procedures
|
| Description |
Ad(moi10)-infected, vehicle-treated
|
| Data processing |
R/Bioconductor GCRMA
|
| |
|
| Submission date |
Jan 12, 2006 |
| Last update date |
Jul 28, 2006 |
| Contact name |
Edmund C Chang |
| Organization name |
Kite Pharma
|
| Street address |
2225 Colorado Ave
|
| City |
Santa Monica |
| State/province |
California |
| ZIP/Postal code |
90404 |
| Country |
USA |
| |
|
| Platform ID |
GPL96 |
| Series (1) |
| GSE4025 |
Gene Expression Preferentially Regulated by Tamoxifen in Breast Cancer Cells |
|
